 |
|
cetuximab
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | Anti-EGFR Monoclonal Antibody
Anti-Epidermal Growth Factor Receptor Monoclonal Antibody
C225 monoclonal antibody
Chimeric Anti-EGFR Monoclonal Antibody
Chimeric Monoclonal Antibody C225
Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer
monoclonal antibody C225 | | | | US brand name: | | Erbitux | | | | Abbreviations: | | Chimeric MoAb C225
MOAB C225 | | | | Code names: | | C225
IMC-C225 | | |
|
|
